Wait, what!? Do you have anything to support this?So lengthy...

Wait, what!? Do you have anything to support this?

So lengthy listing delays likely and Medcan acquisition gone. Some say a lot less dilution but it's still near 50% given the other acquisitions isn't it? Remember MCL alone is +1.2B shares. But speaking of MCL, I wonder what they think of these FURTHER delays and change in direction? Remember they're already in a dispute with CGB over 'milestone' share issue based on the Medcan licence. I wonder how they now feel since getting in bed with QBL??

With shareholder approval necessary, additional ASX waivers, and the nature of these latest changes, is it simply a matter of supplementary prospectus 11, 12, .....? Or will they have to start all over? Anyone? In any case it would appear to be mid-late 2019 at least for trading in my opinion. This might put a squeeze on many things including funds since all these extra staff, research funding, AGMPL fees and so forth...

DYOR